Treatment News : Insufficient Evidence to Support Universal HIV Treatment?

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » August 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

August 29, 2013

Insufficient Evidence to Support Universal HIV Treatment?

A group of HIV experts believes there is not yet enough evidence to support a recommendation of universal antiretroviral treatment regardless of CD4 levels, aidsmap reports. Publishing their argument in the journal AIDS, a group of researchers from the United Kingdom, Australia and Brazil have critiqued various inconsistencies in several global bodies’ policies on when people with HIV should start treatment. The scientists reason that if these organizations used more exacting standards to rate the evidence on when to start treatment their recommendations would prove more in line with one another’s.

The guidelines discussed in the article include those of the United States Department of Health and Human Services, The International Antiviral Society USA, The World Health Organization (which recently recommended all people with HIV begin ARVs at 500 or fewer CD4s), the European AIDS Clinical Society and The British HIV Association.

The paper’s authors point out that there are no published results from a randomized controlled trial (RCT)—the gold standard of scientific research—that assess the risks and benefits of beginning treatment before CD4s hit 350. Among the four available observational cohort studies (which produce a less sterling form of scientific proof) addressing this concern, just two showed a higher death rate among those starting therapy after the 350 benchmark. Only one study showed a benefit of beginning therapy before CD4s drop below 500.

There are, however, two RCTs currently examining the difference of beginning therapy before or after CD4s fall below 350, with results expected in 2014 and 2016.

To read the aidsmap story, click here.

To read the AIDS article abstract, click here.

Search: Universal HIV treatment, antiretrovirals, AIDS, CD4 levels, aidsmap, United States Department of Health and Human Services, The International Antiviral Society USA, The World Health Organization, European AIDS Clinical Society and The British HIV Association.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    adoniz89
    san dimas
    California


    Sin_Grinder
    Reno
    Nevada


    Fred9774
    Brooklyn
    New York


    robert12
    Queens
    New York
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Do you work with your doc to design your own treatment regimen?
Yes
No

Survey
PrEP Course

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.